MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Charles River Laboratories International, Inc. Common Stock (NY:CRL)

175.55 +0.48 (+0.27%)
Official Closing Price Updated: 7:00 PM EDT, Apr 9, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Charles River Laboratories International, Inc. Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
20 21 Next >
News headline image
Charles River Advances Cardiovascular Health Awareness Through Support of the American Heart Association
From Charles River Laboratories International, Inc.
Via Business Wire
News headline image
Guardant Health, Organon, Fortrea, QuidelOrtho, and Charles River Laboratories Stocks Trade Down, What You Need To Know
What Happened? A number of stocks fell in the afternoon session after a proposed 2027 federal budget revealed significant spending cuts for key health agenci... 
Via StockStory
Topics Government Stocks
Uncover the latest developments among S&P500 stocks in today's session. ↗
Via Chartmill
Stay informed with the top movers within the S&P500 index on Monday. ↗
Via Chartmill
Which S&P500 stocks have an unusual volume on Wednesday? ↗
Via Chartmill
Charles River Laboratories (NYSE:CRL) Reports Mixed Q4 2025 Results, Guides for 2026 Growth ↗
Via Chartmill
Monday's session: gap up and gap down stock in the S&P500 index ↗
Via Chartmill
News headline image
1 Cash-Producing Stock with Exciting Potential and 2 Facing Headwinds
Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it eff... 
Via StockStory
News headline image
RadNet, Evolent Health, Illumina, Charles River Laboratories, and Repligen Stocks Trade Down, What You Need To Know
What Happened? A number of stocks fell in the afternoon session after major indices including the S&P 500 and Dow Jones Industrial Average fell sharply as in... 
Via StockStory
Topics Economy Government Stocks
News headline image
1 Value Stock on Our Buy List and 2 We Turn Down
Value stocks typically trade at discounts to the broader market, offering patient investors the opportunity to buy businesses when they’re out of favor. The ... 
Via StockStory
Movers and shakers in today's after-hours session for S&P500 stocks? ↗
Via Chartmill
Which stocks are moving after the closing bell on Monday? ↗
Via Chartmill
Explore the top gainers and losers within the S&P500 index in today's session. ↗
Via Chartmill
These S&P500 stocks are moving in today's session ↗
Via Chartmill
News headline image
3 Reasons CRL is Risky and 1 Stock to Buy Instead
Over the past six months, Charles River Laboratories has been a great trade, beating the S&P 500 by 7.5%. Its stock price has climbed to $168.91, representin... 
Via StockStory
Topics Stocks
Explore the top gainers and losers within the S&P500 index in today's session. ↗
Via Chartmill
News headline image
A Look Back at Drug Development Inputs & Services Stocks’ Q4 Earnings: Charles River Laboratories (NYSE:CRL) Vs The Rest Of The Pack
Via StockStory
News headline image
Charles River Laboratories to Present at TD Cowen and Barclays Conferences
From Charles River Laboratories International, Inc.
Via Business Wire
News headline image
Charles River Laboratories Provides Update on Planned Divestitures
From Charles River Laboratories International, Inc.
Via Business Wire
News headline image
Integra LifeSciences, Enovis, BrightSpring Health Services, IQVIA, and Charles River Laboratories Shares Plummet, What You Need To Know
A number of stocks fell in the morning session after the Trump administration's announcement of new global tariffs reignited trade policy uncertainty. The move came swiftly after the Supreme Court... 
Via StockStory
Topics Government World Trade
News headline image
CRL Q4 Deep Dive: Flat Sales and Margin Pressures as Biotech Demand Recovers
Lab services company Charles River Laboratories (NYSE:CRL) reported revenue ahead of Wall Street’s expectations in Q4 CY2025, but sales were flat year on year at $994.2 million. Its non-GAAP profit of... 
Via StockStory
What's going on in today's session: S&P500 movers ↗
Via Chartmill
Wednesday's session: gap up and gap down stock in the S&P500 index ↗
Via Chartmill
News headline image
Charles River (CRL) Earnings Call Transcript ↗
Charles River (CRL) Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Charles River Laboratories (NYSE:CRL) Beats Q4 CY2025 Sales Expectations
Lab services company Charles River Laboratories (NYSE:CRL) reported revenue ahead of Wall Street’s expectations in Q4 CY2025, but sales were flat year on year at $994.2 million. Its non-GAAP profit of... 
Via StockStory
News headline image
Charles River Laboratories Announces Executive Appointments
From Charles River Laboratories International, Inc.
Via Business Wire
News headline image
Charles River Laboratories Announces Fourth-Quarter and Full-Year 2025 Results and Provides 2026 Guidance
From Charles River Laboratories International, Inc.
Via Business Wire
News headline image
Charles River Laboratories (CRL) Q4 Earnings: What To Expect
Lab services company Charles River Laboratories (NYSE:CRL) will be reporting results this Wednesday before the bell. Here’s what to expect. 
Via StockStory
Topics World Trade
Let's take a look at the S&P500 stocks that are experiencing unusual volume in today's session. ↗
Via Chartmill
News headline image
Halper Sadeh LLC Encourages Charles River Laboratories International, Inc. Shareholders to Contact the Firm to Discuss Their Rights
Shareholders should contact the firm immediately as there may be limited time to enforce your rights 
From Halper Sadeh LLC
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9
...
20 21 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story